Essential Pharma Acquired by EUR 600m Vehicle in Yana Investment Exit

Deal News | Dec 12, 2024 | Yana Investment Partners

Yana Investment Partners successfully exited their investment in Essential Pharma, a company they acquired in 2019 alongside their partner Gyrus. Over the past years, the firm helped transform Essential Pharma into a global specialty pharmaceutical group that focuses on niche and rare disease therapeutic areas. The exit was achieved through a sale to a EUR 600 million continuation vehicle, marking a significant milestone for the investment firm. This transaction underscores Yana's strategy of collaborating closely with leadership teams to drive growth and value creation.

Sectors

Pharmaceuticals
Private Equity

Geography

Global – The article discusses the transformation of Essential Pharma into a global specialty pharma group, indicating the impact on the global market.
Europe – The transaction involved a EUR 600 million vehicle, indicating a European dimension to the financial aspects of the deal.

Industry

Pharmaceuticals – This article relates to the pharmaceuticals industry as it discusses Essential Pharma, a company involved in providing solutions for niche and rare disease therapeutic areas.
Private Equity – Private equity is relevant to this article as it involves Yana Investment Partners exiting an investment by selling Essential Pharma to a continuation vehicle.

Financials

EUR 600 million – The value of the continuation vehicle that acquired Essential Pharma from Yana Investment Partners.

Participants

Name	Role	Type	Description
Yana Investment Partners	Selling Company	Company	A private equity firm that advised the funds which exited the investment in Essential Pharma.
Essential Pharma	Target Company	Company	A global specialty pharma group focused on niche and rare disease therapeutic areas.
Gyrus	Investment Partner	Company	An investment partner that worked closely with Essential Pharma's leadership for its transformation.